Prostrate

The prostate is a small, walnut-shaped gland in the male reproductive system, located below the bladder and surrounding the urethra. It plays a vital role in the production of seminal fluid, contributing to sperm viability and fertility. Understanding its anatomy and function is essential for diagnosing and managing common prostatic disorders.

Anatomy of the Prostate

Gross Anatomy

The prostate is approximately the size of a walnut in healthy adult males, weighing 20 to 30 grams. It surrounds the prostatic urethra and is divided into distinct anatomical zones:

• Peripheral Zone: Located posteriorly and laterally, this zone is the most common site of prostate cancer.
• Central Zone: Surrounds the ejaculatory ducts and constitutes about 25% of the prostate volume.
• Transitional Zone: Surrounds the urethra and is the primary site for benign prostatic hyperplasia.
• Anterior Fibromuscular Stroma: Non-glandular tissue located anteriorly, providing structural support.

Relations with Surrounding Structures

The prostate is closely related to several important anatomical structures, which influence its function and clinical considerations:

• Bladder: The prostate lies immediately below the bladder neck, affecting urinary flow.
• Urethra: The prostatic urethra passes through the gland, serving as a conduit for urine and semen.
• Seminal Vesicles: Located posterolaterally, they contribute to seminal fluid and join the ejaculatory ducts within the prostate.
• Rectum: Positioned posteriorly, allowing digital rectal examination for clinical assessment.

Blood Supply, Lymphatics, and Innervation

The prostate receives arterial blood primarily from the inferior vesical and middle rectal arteries. Venous drainage occurs via the prostatic venous plexus, which communicates with the internal vertebral venous plexus. Lymphatic drainage follows the obturator and internal iliac lymph nodes. Innervation is provided by the autonomic pelvic plexus, influencing glandular secretions and urinary function.

Histology and Cellular Structure

Epithelial Cells

The prostate is composed of glandular epithelium embedded within a fibromuscular stroma. The epithelial component includes:

• Secretory Cells: Columnar cells responsible for producing prostatic fluid, rich in enzymes and proteins that support sperm viability.
• Basal Cells: Cuboidal or low columnar cells providing structural support and acting as progenitors for secretory cells.

Stroma

The stromal component consists of smooth muscle and connective tissue, providing structural integrity and facilitating the expulsion of prostatic secretions during ejaculation.

• Smooth Muscle: Contracts during ejaculation to expel prostatic fluid into the urethra.
• Connective Tissue: Provides support for the glandular elements and maintains overall gland architecture.

Physiology and Function

Secretory Function

The primary function of the prostate is the production of prostatic fluid, which constitutes approximately 20-30% of the ejaculate volume. This fluid contains enzymes such as prostate-specific antigen (PSA), citric acid, zinc, and other proteins that enhance sperm motility, viability, and fertilization capacity.

• Prostatic fluid composition: Enzymes, proteins, minerals, and electrolytes.
• Role in semen: Provides a medium for sperm transport and protection within the female reproductive tract.

Endocrine Regulation

Prostate growth and secretory activity are heavily dependent on androgens, primarily testosterone and its more active metabolite, dihydrotestosterone (DHT). Androgen receptors in epithelial and stromal cells mediate the effects of these hormones, regulating cellular proliferation, differentiation, and secretion.

• Androgen dependence: Essential for normal development and maintenance of prostate tissue.
• Role of testosterone and DHT: Stimulate epithelial and stromal cell activity and secretory function.

Common Diseases and Disorders

Benign Prostatic Hyperplasia (BPH)

BPH is a non-malignant enlargement of the prostate, commonly affecting the transitional zone. It can cause obstruction of the prostatic urethra and result in lower urinary tract symptoms such as difficulty in urination, weak stream, and increased frequency.

Prostate Cancer

Prostate cancer is a malignant proliferation of prostate epithelial cells, most commonly arising in the peripheral zone. Risk factors include age, family history, and genetic mutations. Early stages are often asymptomatic, while advanced disease can present with urinary symptoms or metastasis, particularly to bone.

Prostatitis

Prostatitis is inflammation of the prostate, which may be acute or chronic. It can be infectious or non-infectious and presents with a variety of urinary and systemic symptoms.

• Acute bacterial prostatitis: Sudden onset, fever, dysuria, and pelvic pain.
• Chronic bacterial prostatitis: Persistent or recurrent urinary tract infections.
• Chronic pelvic pain syndrome: Non-bacterial, long-standing pelvic discomfort with urinary symptoms.

Clinical Presentation

Lower Urinary Tract Symptoms (LUTS)

Prostatic disorders commonly present with lower urinary tract symptoms resulting from obstruction or irritation of the urethra. Symptoms can be categorized as obstructive or irritative.

• Obstructive symptoms: Weak urinary stream, hesitancy, incomplete bladder emptying, and straining.
• Irritative symptoms: Urgency, frequency, nocturia, and dysuria.

Systemic Symptoms

Some prostatic conditions, particularly infections or malignancy, may present with systemic or generalized symptoms.

• Fever, malaise, and pelvic discomfort in acute prostatitis.
• Weight loss, fatigue, or bone pain in metastatic prostate cancer.

Diagnosis

Clinical Examination

Physical assessment is essential for initial evaluation of prostate disorders. Digital rectal examination (DRE) allows assessment of prostate size, texture, and nodularity, aiding in the detection of BPH or malignancy.

Laboratory Investigations

• Prostate-specific antigen (PSA): A serum marker elevated in BPH, prostatitis, and prostate cancer.
• Urine analysis and culture: Useful in diagnosing bacterial prostatitis or urinary tract infections.

Imaging and Biopsy

Advanced diagnostic tools help confirm disease, assess severity, and guide treatment planning.

• Ultrasound: Transrectal ultrasound (TRUS) provides evaluation of prostate volume and structural abnormalities.
• MRI: Multiparametric MRI aids in detection and staging of prostate cancer.
• Prostate biopsy: Histopathological confirmation of malignancy, typically guided by TRUS or MRI.

Management

Medical Management

Medical therapy is often the first-line approach for managing benign and inflammatory prostatic conditions, as well as certain cases of prostate cancer.

• Alpha-blockers: Relax smooth muscle in the prostate and bladder neck to improve urinary flow in BPH.
• 5-alpha reductase inhibitors: Reduce prostate volume over time by blocking the conversion of testosterone to DHT.
• Antibiotics: Treat bacterial prostatitis, tailored according to urine culture results.
• Hormonal therapy: Androgen deprivation therapy for advanced or metastatic prostate cancer.

Surgical Management

Surgical intervention is indicated for refractory symptoms, significant obstruction, or confirmed malignancy.

• Transurethral resection of the prostate (TURP): Standard procedure for BPH to relieve obstruction.
• Prostatectomy: Partial or radical removal for localized or advanced prostate cancer.
• Minimally invasive procedures: Laser therapy, prostatic urethral lift, or microwave therapy for BPH in selected patients.

Prevention and Screening

Screening Guidelines

Early detection of prostate disease, especially cancer, improves outcomes. Screening includes clinical and laboratory assessments.

• Prostate-specific antigen (PSA) testing: Recommended for men over 50, or earlier in high-risk individuals.
• Digital rectal examination (DRE): Provides additional clinical assessment alongside PSA.

Lifestyle and Risk Reduction

Lifestyle modifications may reduce the risk of prostatic disorders or delay progression.

• Maintaining a healthy diet rich in fruits, vegetables, and low in saturated fats.
• Regular exercise to improve overall health and urinary function.
• Managing comorbidities such as obesity, hypertension, and diabetes.

Prognosis and Complications

Benign Conditions

Patients with benign prostatic hyperplasia or mild prostatitis generally have a favorable prognosis with appropriate medical or minimally invasive treatment. Symptom control and quality of life can usually be maintained.

Malignant Conditions

Prostate cancer prognosis depends on stage, grade, and response to treatment. Localized disease has a high survival rate, whereas advanced or metastatic cancer carries a less favorable prognosis.

• Metastasis: Commonly to bone, particularly the spine and pelvis.
• Recurrence: May occur after surgery or radiation, necessitating close follow-up.

References

1. Campbell-Walsh Urology. 12th ed. Wein AJ, Kavoussi LR, Partin AW, Peters CA, editors. Philadelphia: Elsevier; 2020.
2. Nelson CP, et al. Epidemiology of Prostate Cancer. Urol Clin North Am. 2018;45(4):469-478.
3. McVary KT, et al. Management of Benign Prostatic Hyperplasia. J Urol. 2011;185(5):1793-1803.
4. Klotz L. Active Surveillance for Prostate Cancer: Rationale and Guidelines. Can Urol Assoc J. 2013;7(11-12):E715-E720.
5. Bhindi B, et al. Prostate Cancer: Clinical Features and Diagnosis. CMAJ. 2018;190(30):E888-E895.
6. Andriole GL, et al. Prostate-Specific Antigen Screening and Prostate Cancer Mortality. N Engl J Med. 2009;360:1310-1319.
7. Strope SA, et al. Surgical Approaches to Benign Prostatic Hyperplasia. Curr Opin Urol. 2013;23(1):1-7.
8. Shahani S, et al. Prostatitis: Diagnosis and Management. Curr Opin Urol. 2016;26(1):6-13.
9. Barry MJ, et al. Evaluation of Lower Urinary Tract Symptoms. N Engl J Med. 2002;347:1352-1359.
10. Heidenreich A, et al. EAU Guidelines on Prostate Cancer. Eur Urol. 2020;79(2):243-262.